Mission
To help Positron Emission Tomography (PET) based molecular imaging realise its full potential in translational experimental medicine by advising organisations how PET could be fully developed and exploited within their individual circumstances.
Our Advice
The advice given by the PRA Company will be aligned to an organisation’s current and projected future investments in PET. This will be within the context of its culture for clinical research, commitment to supporting drug development, ambitions to obtain research funding, undertake commissioned studies and to have a presence nationally and internationally.
The PRA Company offers a new way in which advice is provided to help organisations develop their portfolio of clinical research applications, formulate scientific and practical strategies along with internal and external recruitment and networking.
​
The advice will be derived through listening to and working with the organisation to review, explore and facilitate its ambitions for PET and help develop the vision and road map for realising these ambitions.
The advice will be based upon experience, access to additional foremost expertise, insight into and vision and enthusiasm for the future developments of PET both in technology and applications along with insight into national and international collaborations.
Who We Will Work With
Based upon past experiences and the nature of the perceived need for advice, the Company is able to work with:
-
Academic clinical research centres
-
Government research funding agencies
-
Medical research charities
-
The pharmaceutical industry
-
The radiological industry
-
Research consortia and collaborative groups
-
Potential research donors.
No enquiry for advice will be considered too small or too big.
​
More information can be found at www.the-pra.co.uk
The PRA Directors
Professor Pat Price' profile
Visiting Professor in the Division of Surgery within the Department of Surgery and Cancer, Imperial College London, Pat Price is an academic clinical oncologist specialising in PET based molecular imaging, advanced radiotherapy techniques and translational research in oncology.
​
She pioneered the use of PET molecular imaging for micro-dosing pharmacokinetic and pharmacokinetic studies of new cancer agents and has one of the best insights into the potential of the application of this technology for oncology drug development. Through the PET Research Advisory Company The PRA, she provides advice to organisations on current and projected future investments in PET.
Professor Price established the European Organization for the Research and Treatment of Cancer (EORTC) Functional Imaging group, developing strategic links between oncologists and imagers and guidelines for PET in clinical trials. She has networked research collaborations with leading academic cancer researchers and service deliverers in the UK.
​
She established the Academic Department of Radiation Oncology and the Wolfson Molecular Imaging Centre at the Christie Hospital, University of Manchester. In 2005 she established the UK Academic Clinical Oncology and Radiobiology Research Network (ACORRN). This was re-launched in 2010 as the charity Action Radiotherapy www.actionradiotherapy.org. It is the UK's only charity dedicated to improving radiotherapy treatment. She is Chair of the trustees.
Professor Price is the co-editor of the standard UK oncology textbook 'Treatment of Cancer', now in its 6th edition. She was President of the British Oncological Association from 2002 to 2004 and was a member of the 2008 UK Research Assessment Exercise oncology subcommittee.
​
She has raised more than £20M in research funding and has also trained 22 clinical research fellows in experimental medicine to research degree level (including 8 international awards).
A recognised opinion leader in PET based molecular imaging in cancer and advanced radiotherapy, she was profiled on CancerWorld.net
Professor Price has over 380 scientific publications and an H index of 50.